-SEC Filing
‘FDA Advisors Weigh Whether Alzheimer’s Drug Leqembi Should Receive Full Approval, Will Make A Final Decision On July 6’ – CNBC
https://www.cnbc.com/2023/06/09/fda-advisors-review-alzheimers-drug-leqembi-for-full-approval.html
The FDA’s independent advisors will make a recommendation on whether Eisai and Biogen’s Alzheimer’s
